At least one of the NKG2D ligands was present on the blast cells’ surface of the majority of AML patients (75%) in the comprehensive study of the mechanisms to evade NKG2D-mediated immunosurveillance during leukemia [111]. This evidence concerns the gene KLRK1 and leukemia.